CombiMatrix Joins CGH Space with Array Genomics Deal to Develop Retardation Dx; CGH IVDs on Deck | GenomeWeb

CombiMatrix Molecular Diagnostics this week entered the array comparative genomic hybridization market by announcing an agreement to manufacture array CGH-based tests for Array Genomics, and appointing as chief scientific officer a former Quest Diagnostics official with expertise in array CGH.

CMDX, a subsidiary of Acacia Research's CombiMatrix group, will now join a market that includes competition from Spectral Genomics, Signature Genomic Laboratories, NimbleGen, Agilent Technologies, Oxford Gene Technology, and others.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.